Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

161. Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong Full Text available with Trip Pro

Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related deaths worldwide. Curative resection is frequently limited in Hong Kong by hepatitis B virus-related cirrhosis, and liver transplantation is the treatment of choice. Liver transplantation has been shown to produce superior oncological benefits, when compared to hepatectomy for HCC. New (...) developments in the context of patient selection criteria, modification of organ allocation, bridging therapy, salvage liver transplantation and pharmaceutical breakthrough have improved the survival of HCC patients. In this article, we will share our experience in transplanting hepatitis B virus-related HCC patients in Hong Kong and discuss the recent progress in several areas of liver transplantation.

2018 Journal of clinical and translational hepatology

162. Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection Full Text available with Trip Pro

Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from Asia-Pacific countries and Russia. In this phase 3, randomized, placebo-controlled, double-blind study, treatment-naive participants with HCV genotype (GT) 1, 4, or 6 infection

2018 Hepatology communications Controlled trial quality: predicted high

163. Sofosbuvir-velpatasvir (Epclusa) - chronic hepatitis C virus (HCV)

Sofosbuvir-velpatasvir (Epclusa) - chronic hepatitis C virus (HCV) Published 9 April 2018 1 Re-Submission sofosbuvir 400mg, velpatasvir 100mg film-coated tablets (Epclusa ® ) SMC No 1271/17 Gilead Sciences Ltd 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a resubmission sofosbuvir (...) -velpatasvir (Epclusa ® ) is accepted for restricted use within NHS Scotland. Indication under review: treatment of chronic hepatitis C virus (HCV) infection in adults. SMC restriction: in patients with genotype 1 or 4 HCV infection. Sofosbuvir-velpatasvir was associated with high rates of sustained virologic suppression in adults with genotype 1 and 4 chronic HCV infection, including those with decompensated cirrhosis. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS

2018 Scottish Medicines Consortium

164. Hepatitis C: sofosbuvir + velpatasvir (Epclusa) represents an advance for some patients

Hepatitis C: sofosbuvir + velpatasvir (Epclusa) represents an advance for some patients Prescrire IN ENGLISH - Spotlight ''Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients'', 1 April 2018 {1} {1} {1} | | > > > Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients The combination sofosbuvir + velpatasvir (Epclusa°) offers a therapeutic advance in the treatment of hepatitis C, especially in patients infected by a genotype 2 virus. But the uncertainty surrounding its adverse effects is unacceptable. Hepatitis C can cause complications such as cirrhosis and liver cancer. Treatment depends on the virus genotype, the severity

2018 Prescrire

165. Sofosbuvir-velpatasvir-voxilaprevir (Vosevi) - chronic hepatitis C virus (HCV)

Sofosbuvir-velpatasvir-voxilaprevir (Vosevi) - chronic hepatitis C virus (HCV) Published 9 April 2018 1 sofosbuvir 400mg, velpatasvir 100mg, voxilaprevir 100mg film-coated tablet (Vosevi ® ) SMC No 1317/18 Gilead Sciences Ltd 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full (...) submission sofosbuvir-velpatasvir-voxilaprevir (Vosevi®) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults. SMC restriction: for patients who: (1) Have failed to achieve a sustained virologic response (SVR) with a direct-acting anti-viral (DAA) or (2) are DAA-naïve, have genotype 3 (GT3) HCV infection, with or without cirrhosis, and are suitable for treatment with an eight-week course. Sofosbuvir-velpatasvir

2018 Scottish Medicines Consortium

166. Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis 4 Scores in Predicting Advanced Liver Fibrosis in Patients with End-stage Renal Disease and Chronic Viral Hepatitis: Experience from Pakistan Full Text available with Trip Pro

Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis 4 Scores in Predicting Advanced Liver Fibrosis in Patients with End-stage Renal Disease and Chronic Viral Hepatitis: Experience from Pakistan The aim was to assess the diagnostic accuracy of APRI and FIB-4 in assessing the stage of liver fibrosis in end stage renal disease (ESRD) patients with chronic viral hepatitis and to compare the two tests with standard tru-cut liver biopsy.The study was conducted (...) at Sindh Institute of Urology and Transplantation Karachi (SIUT) from May 2010 to May 2014. All ESRD patients, being considered as candidates for renal transplantation and in whom liver biopsy was performed were included. Fibrosis stage was assessed on liver biopsy using Ishak scoring system. The serum transaminases and platelet counts were used to calculate APRI and FIB-4 scores.Out of 109 patients, hepatitis C and B virus infections were present in 104 (95.4%) and 3(2.8%), respectively, while 2 (1.8

2018 Journal of translational internal medicine

167. Liver‐enriched transcription factor expression relates to chronic hepatic failure in humans Full Text available with Trip Pro

Liver‐enriched transcription factor expression relates to chronic hepatic failure in humans The mechanisms by which the liver fails in end-stage liver disease remain elusive. Disruption of the transcription factor network in hepatocytes has been suggested to mediate terminal liver failure in animals. However, this hypothesis remains unexplored in human subjects. To study the relevance of transcription factor expression in terminal stages of chronic liver failure in humans, we analyzed (...) the expression of liver-enriched transcription factors (LETFs) hepatocyte nuclear factor (HNF)4α, HNF1α, forkhead box protein A2 (FOXA2), CCAAT/enhancer-binding protein (CEBP)α, and CEBPβ. We then selected downstream genes responsible for some hepatic functions (ornithine transcarbamylase [OTC], cytochrome P450 3A4 [CYP3A4], coagulation factor VII [F7], cadherin 1 [CDH1], phospho-ezrin (Thr567)/radixin (Thr564)/moesin (Thr558) [p-ERM], phospho-myosin light chain [p-MLC], low-density lipoprotein receptor

2018 Hepatology communications

168. Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist Full Text available with Trip Pro

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated alanine aminotransferases (ALTs) associated with LY2409021. Patients participated in a 6 (...) -week placebo-controlled trial (I1R-MC-GLDI [GLDI], n = 246) and a 52-week placebo- and active comparator-controlled trial (I1R-MC-GLDJ [GLDJ], n = 158). GLDJ had endpoints at 6 months, including measures of hepatic fat fraction (HFF) by magnetic resonance imaging. The five genes tested were patatin-like phospholipase domain containing 3 (PNPLA3) (rs738409 and rs738491), transmembrane 6 superfamily member 2 (TM6SF2) (rs58542926), peroxisome proliferative activated receptor gamma coactivator 1 alpha

2018 Hepatology communications Controlled trial quality: uncertain

169. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B Full Text available with Trip Pro

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B 29577026 2018 11 14 2225-0719 6 1 2018 Mar 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. 1-10 10.14218/JCTH.2017.00073 Zhang Wenhong W Huashang Hospital of Fudan University, Shanghai, China. Zhang Dazhi D The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Dou Xiaoguang X Shengjing (...) Consensus Hepatitis B Interferons Therapy The authors have no conflict of interests related to this publication. 2017 11 08 2018 02 05 2018 02 09 2018 3 27 6 0 2018 3 27 6 0 2018 3 27 6 1 ppublish 29577026 10.14218/JCTH.2017.00073 JCTH.2017.00073 PMC5862993 Gut. 2013 Feb;62(2):290-8 22859496 Hepatology. 2009 Apr;49(4):1151-7 19115222 J Infect Dis. 2016 Mar 15;213(6):966-74 26582959 Gastroenterology. 2009 Dec;137(6):2002-9 19737568 Zhonghua Gan Zang Bing Za Zhi. 2010 Jul;18(7):495-7 20678437 J Viral

2018 Journal of clinical and translational hepatology

170. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study Full Text available with Trip Pro

HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study Background and Aims: Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in chronic hepatitis B patients with partial response to a previous NA (...) . Methods: Hepatitis B e antigen (HBeAg)-positive patients who achieved HBeAg loss and hepatitis B virus DNA <200 IU/mL with previous adefovir, lamivudine or entecavir treatment were randomized 1:1 to receive Peg-IFN alfa-2a for 48 (n = 153) or 96 weeks (n = 150). The primary endpoint of this study was HBsAg loss at end of treatment. The ClinicalTrials.gov identifier is NCT01464281. Results: At the end of 48 and 96 weeks' treatment, 14.4% (22/153) and 20.7% (31/150) of patients, respectively, who

2018 Journal of clinical and translational hepatology Controlled trial quality: uncertain

171. Increase in hepatic and decrease in peripheral insulin clearance characterize abnormal temporal patterns of serum insulin in diabetic subjects Full Text available with Trip Pro

Increase in hepatic and decrease in peripheral insulin clearance characterize abnormal temporal patterns of serum insulin in diabetic subjects Insulin plays a central role in glucose homeostasis, and impairment of insulin action causes glucose intolerance and leads to type 2 diabetes mellitus (T2DM). A decrease in the transient peak and sustained increase of circulating insulin following an infusion of glucose accompany T2DM pathogenesis. However, the mechanism underlying this abnormal temporal (...) pattern of circulating insulin concentration remains unknown. Here we show that changes in opposite direction of hepatic and peripheral insulin clearance characterize this abnormal temporal pattern of circulating insulin concentration observed in T2DM. We developed a mathematical model using a hyperglycemic and hyperinsulinemic-euglycemic clamp in 111 subjects, including healthy normoglycemic and diabetic subjects. The hepatic and peripheral insulin clearance significantly increase and decrease

2018 NPJ systems biology and applications

172. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. Full Text available with Trip Pro

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin.In this multicenter, double-blind clinical trial performed in Thailand, we randomly assigned hepatitis B e antigen (HBeAg)-positive pregnant women with an alanine aminotransferase level of 60 IU or less per liter to receive tenofovir (...) disoproxil fumarate (TDF) or placebo from 28 weeks of gestation to 2 months post partum. Infants received hepatitis B immune globulin at birth and hepatitis B vaccine at birth and at 1, 2, 4, and 6 months. The primary end point was a hepatitis B surface antigen (HBsAg)-positive status in the infant, confirmed by the HBV DNA level at 6 months of age. We calculated that a sample of 328 women would provide the trial with 90% power to detect a difference of at least 9 percentage points in the transmission

2018 NEJM Controlled trial quality: predicted high

173. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis Full Text available with Trip Pro

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation for the treatment of human NASH fibrosis. We assessed (...) weeks based on histologic and molecular markers, mirroring observations in human NASH CVC trials. CVC also directly inhibited the profibrotic gene signature of transforming growth factor-β-stimulated primary mouse hepatic stellate cells in vitro. Conclusion: CVC is a novel therapeutic agent that is associated with reduced fibrosis despite ongoing steatohepatitis. Its ability to alter intrahepatic macrophage populations and inhibit profibrogenic genes in hepatic stellate cells in NASH livers may

2018 Hepatology communications

174. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Full Text available with Trip Pro

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Given the high mortality rate for patients with end-stage kidney disease receiving dialysis and the efficacy and safety of hepatitis C virus (HCV) treatments, discarded kidneys from HCV-infected donors may be a neglected public health resource.To determine the tolerability and feasibility of using direct-acting antivirals (DAAs

2018 Annals of Internal Medicine

175. Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination Full Text available with Trip Pro

Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination 29682622 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination. 15 10.21037/tgh.2018.02.03 Lee Mei-Hsuan MH Institute of Clinical Medicine, National (...) Yang-Ming University, Taipei. eng Editorial Comment 2018 03 05 China Transl Gastroenterol Hepatol 101683450 2415-1289 Gastroenterology. 2017 Oct;153(4):996-1005.e1 28642197 Conflicts of Interest: The author has no conflicts of interest to declare. 2018 02 04 2018 02 19 2018 4 24 6 0 2018 4 24 6 0 2018 4 24 6 1 epublish 29682622 10.21037/tgh.2018.02.03 tgh-03-2018.02.03 PMC5897667 JAMA. 2012 Dec 26;308(24):2584-93 23268517 J Viral Hepat. 2018 Mar;25(3):228-235 29053909 Epidemiol Rev. 2015;37:131-43

2018 Translational gastroenterology and hepatology

176. Sofosbuvir?velpatasvir?voxilaprevir for treating chronic hepatitis C

Sofosbuvir?velpatasvir?voxilaprevir for treating chronic hepatitis C Sofosbuvir–v Sofosbuvir–velpatasvir–v elpatasvir–vo oxilapre xilaprevir for vir for treating chronic hepatitis C treating chronic hepatitis C T echnology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

177. Sofosbuvir (Sovaldi) - for the treatment of chronic hepatitis C in adolescents

Sofosbuvir (Sovaldi) - for the treatment of chronic hepatitis C in adolescents Published 12 March 2018 Statement of Advice: sofosbuvir 400mg film-coated tablets (Sovaldi ® ) SMC No 1326/18 Gilead Sciences Ltd 9 February 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation sofosbuvir (Sovaldi ® ) is not recommended for use within NHS Scotland. Indication under review: In combination with other medicinal products for the treatment of chronic hepatitis C

2018 Scottish Medicines Consortium

178. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort Full Text available with Trip Pro

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child-Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus

2018 Hepatology communications

179. Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis Full Text available with Trip Pro

Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis Autoimmune hepatitis (AIH) is an immune-mediated liver disease currently treated by immunosuppressive medications with significant side effects. Thus, novel mechanistic treatments are greatly needed. We performed prospective deep immunophenotyping of blood immune cells in patients with acute AIH before and after corticosteroid therapy. Blood samples from 26 patients (...) . Conclusion: Activated effector NK cells, which correlate with biochemical measurements of hepatitis, and exhausted memory Tregs are increased in the blood of patients with treatment-naive AIH and decline with corticosteroid therapy. Inadequate regulation of NK cells by exhausted FOXP3pos Tregs may play a role in AIH pathogenesis and contribute to liver injury. (Hepatology Communications 2018;2:421-436).

2018 Hepatology communications

180. New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome Full Text available with Trip Pro

New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are two major immune-mediated chronic liver diseases. Overlap syndrome (OS) is diagnosed if patients have features of both AIH and PBC; however, there is no consensus on the definition or diagnostic criteria for OS. Here, we report a new scoring classification for OS and evaluate its usefulness. This new scoring classification (...) was developed by modifying the International Autoimmune Hepatitis Group classification by selecting histologic features of AIH and PBC along with modifications of biochemical and immunologic characteristics. We evaluated 272 patients with chronic liver disease, including 105 with AIH, 102 with PBC, and 65 with OS. The best performance for the diagnosis of OS was noted among patients with an overlap score of ≥21 who had a sensitivity of 98.5%, a specificity of 92.8%, a positive predictive value of 81.0

2018 Hepatology communications